NRF1 and Miyoshi myopathy: This compound also blocks translocation from the ER and cytoplasmic processing of NRF1 and has cytotoxic effects on a broad panel of PIs adapted and naive myeloma cell lines as well as on cells derived directly from patient samples with MM before and after BTZ therapy [230, 232].